Becton, Dickinson and (NYSE:BDX) Price Target Lowered to $270.00 at Evercore ISI

Becton, Dickinson and (NYSE:BDXGet Rating) had its price objective cut by Evercore ISI to $270.00 in a research note issued to investors on Wednesday morning, Stock Target Advisor reports.

Several other research analysts have also recently weighed in on BDX. Cowen decreased their price target on shares of Becton, Dickinson and to $255.00 in a report on Wednesday. StockNews.com cut shares of Becton, Dickinson and from a buy rating to a hold rating in a report on Friday, November 11th. Piper Sandler decreased their price target on shares of Becton, Dickinson and from $255.00 to $245.00 and set a neutral rating on the stock in a report on Thursday, November 10th. The Goldman Sachs Group increased their target price on Becton, Dickinson and from $278.00 to $319.00 and gave the company a buy rating in a research note on Tuesday, August 16th. Finally, Morgan Stanley increased their target price on Becton, Dickinson and from $272.00 to $275.00 and gave the company an overweight rating in a research note on Tuesday, October 11th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of Hold and a consensus price target of $272.40.

Becton, Dickinson and Trading Up 2.6 %

Shares of BDX stock opened at $225.59 on Wednesday. The company’s fifty day simple moving average is $231.12 and its two-hundred day simple moving average is $243.56. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.04 and a quick ratio of 0.63. Becton, Dickinson and has a 1 year low of $215.90 and a 1 year high of $280.62. The stock has a market capitalization of $64.34 billion, a price-to-earnings ratio of 38.37, a PEG ratio of 2.52 and a beta of 0.61.

Becton, Dickinson and (NYSE:BDXGet Rating) last issued its earnings results on Thursday, November 10th. The medical instruments supplier reported $2.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.74 by $0.01. Becton, Dickinson and had a net margin of 9.16% and a return on equity of 14.47%. The business had revenue of $4.76 billion for the quarter, compared to analysts’ expectations of $4.72 billion. During the same quarter in the previous year, the firm posted $2.15 EPS. The business’s revenue for the quarter was down 6.6% compared to the same quarter last year. As a group, analysts anticipate that Becton, Dickinson and will post 11.94 earnings per share for the current year.

Becton, Dickinson and Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 30th. Stockholders of record on Friday, December 9th will be issued a dividend of $0.91 per share. This is a positive change from Becton, Dickinson and’s previous quarterly dividend of $0.87. This represents a $3.64 dividend on an annualized basis and a dividend yield of 1.61%. The ex-dividend date is Thursday, December 8th. Becton, Dickinson and’s dividend payout ratio is currently 59.18%.

Hedge Funds Weigh In On Becton, Dickinson and

Institutional investors have recently bought and sold shares of the stock. Park Avenue Securities LLC increased its stake in shares of Becton, Dickinson and by 317.0% during the first quarter. Park Avenue Securities LLC now owns 4,328 shares of the medical instruments supplier’s stock valued at $1,151,000 after purchasing an additional 3,290 shares in the last quarter. Whittier Trust Co. increased its stake in shares of Becton, Dickinson and by 0.7% during the first quarter. Whittier Trust Co. now owns 7,160 shares of the medical instruments supplier’s stock valued at $1,905,000 after purchasing an additional 47 shares in the last quarter. Arkadios Wealth Advisors bought a new position in shares of Becton, Dickinson and during the first quarter valued at approximately $594,000. Signaturefd LLC increased its position in shares of Becton, Dickinson and by 10.3% during the first quarter. Signaturefd LLC now owns 3,028 shares of the medical instruments supplier’s stock valued at $805,000 after acquiring an additional 283 shares in the last quarter. Finally, Personal CFO Solutions LLC increased its position in shares of Becton, Dickinson and by 24.8% during the first quarter. Personal CFO Solutions LLC now owns 1,061 shares of the medical instruments supplier’s stock valued at $282,000 after acquiring an additional 211 shares in the last quarter. 86.74% of the stock is owned by institutional investors.

About Becton, Dickinson and

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Recommended Stories

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.